|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 45, 2071-2079, November 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology
Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4
,
* Touchstone Center for Diabetes Research, University of Texas Southwestern Medical Center, Dallas, TX 75390-8854
Departments of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8854
Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8854
1 To whom correspondence should be addressed. e-mail: cai.li{at}utsouthwestern.edu
Angiopoietin-like protein 4 (Angptl4) is the second member of the angiopoietin-like family of proteins previously shown to increase plasma triglyceride (TG) levels in vivo. We recently reported that Angptl4 is a variable-sized oligomer formed by intermolecular disulfide bonds and undergoes regulated proteolytic processing upon secretion. We now show that adenoviral overexpression of Angptl4 potently increases plasma TG levels by a mechanism independent of food intake or hepatic VLDL secretion. We determined that cysteine residues at positions 76 and 80 of Angptl4, conserved among mouse, rat, and human, are required to form higher order structures. By generating adenoviral expression vectors of Angptl4 containing different epitope tags at both N and C termini, we show that loss of oligomerization results in decreased stability of the N-terminal coiled-coil domain of Angptl4 as well as decreased ability to increase plasma TG levels, suggesting that intermolecular disulfide bond formation plays important roles in determining the magnitude of the hyperlipidemic effect of Angptl4.
Because Angptl4 is more potent than Angptl3 in increasing plasma TG levels in mice, inappropriate oligomerization of Angptl4 could be associated with disorders of lipid metabolism in vivo.
Supplementary key words lipoprotein lipase • plasma triglyceride • disulfide bond
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E-C. Lee, U. Desai, G. Gololobov, S. Hong, X. Feng, X.-C. Yu, J. Gay, N. Wilganowski, C. Gao, L.-L. Du, et al. Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL) J. Biol. Chem., May 15, 2009; 284(20): 13735 - 13745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yin, S. Romeo, S. Chang, N. V. Grishin, H. H. Hobbs, and J. C. Cohen Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function J. Biol. Chem., May 8, 2009; 284(19): 13213 - 13222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-h. Yau, Y. Wang, K. S. L. Lam, J. Zhang, D. Wu, and A. Xu A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization J. Biol. Chem., May 1, 2009; 284(18): 11942 - 11952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chomel, A. Cazes, C. Faye, M. Bignon, E. Gomez, C. Ardidie-Robouant, A. Barret, S. Ricard-Blum, L. Muller, S. Germain, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity FASEB J, March 1, 2009; 23(3): 940 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Staiger, C. Haas, J. Machann, R. Werner, M. Weisser, F. Schick, F. Machicao, N. Stefan, A. Fritsche, and H.-U. Haring Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator-Activated Receptor (PPAR)-{delta} and Is of Metabolic Relevance in Humans Diabetes, March 1, 2009; 58(3): 579 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shan, X.-C. Yu, Z. Liu, Y. Hu, L. T. Sturgis, M. L. Miranda, and Q. Liu The Angiopoietin-like Proteins ANGPTL3 and ANGPTL4 Inhibit Lipoprotein Lipase Activity through Distinct Mechanisms J. Biol. Chem., January 16, 2009; 284(3): 1419 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Talmud, M. Smart, E. Presswood, J. A. Cooper, V. Nicaud, F. Drenos, J. Palmen, M. G. Marmot, S. M. Boekholdt, N. J. Wareham, et al. ANGPTL4 E40K and T266M: Effects on Plasma Triglyceride and HDL Levels, Postprandial Responses, and CHD Risk Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Yang, Y. Wang, K. S.L. Lam, M.-H. Yau, K. K.Y. Cheng, J. Zhang, W. Zhu, D. Wu, and A. Xu Suppression of the Raf/MEK/ERK Signaling Cascade and Inhibition of Angiogenesis by the Carboxyl Terminus of Angiopoietin-Like Protein 4 Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 835 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lichtenstein, J. F.P. Berbee, S. J. van Dijk, K. W. van Dijk, A. Bensadoun, I. P. Kema, P. J. Voshol, M. Muller, P. C.N. Rensen, and S. Kersten Angptl4 Upregulates Cholesterol Synthesis in Liver via Inhibition of LPL- and HL-Dependent Hepatic Cholesterol Uptake Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Desai, E-C. Lee, K. Chung, C. Gao, J. Gay, B. Key, G. Hansen, D. Machajewski, K. A. Platt, A. T. Sands, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice PNAS, July 10, 2007; 104(28): 11766 - 11771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mandard, F. Zandbergen, E. van Straten, W. Wahli, F. Kuipers, M. Muller, and S. Kersten The Fasting-induced Adipose Factor/Angiopoietin-like Protein 4 Is Physically Associated with Lipoproteins and Governs Plasma Lipid Levels and Adiposity J. Biol. Chem., January 13, 2006; 281(2): 934 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koster, Y. B. Chao, M. Mosior, A. Ford, P. A. Gonzalez-DeWhitt, J. E. Hale, D. Li, Y. Qiu, C. C. Fraser, D. D. Yang, et al. Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism Endocrinology, November 1, 2005; 146(11): 4943 - 4950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Crawford and J. I. Gordon From The Cover: Microbial regulation of intestinal radiosensitivity PNAS, September 13, 2005; 102(37): 13254 - 13259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ge, J.-Y. Cha, H. Gopal, C. Harp, X. Yu, J. J. Repa, and C. Li Differential regulation and properties of angiopoietin-like proteins 3 and 4 J. Lipid Res., July 1, 2005; 46(7): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-T. Kim, H.-H. Choi, M. O. Steinmetz, B. Maco, R. A. Kammerer, S. Y. Ahn, H.-Z. Kim, G. M. Lee, and G. Y. Koh Oligomerization and Multimerization Are Critical for Angiopoietin-1 to Bind and Phosphorylate Tie2 J. Biol. Chem., May 20, 2005; 280(20): 20126 - 20131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Xu, M. C. Lam, K. W. Chan, Y. Wang, J. Zhang, R. L. C. Hoo, J. Y. Xu, B. Chen, W.-S. Chow, A. W. K. Tso, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice PNAS, April 26, 2005; 102(17): 6086 - 6091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yu, S. C. Burgess, H. Ge, K. K. Wong, R. H. Nassem, D. J. Garry, A. D. Sherry, C. R. Malloy, J. P. Berger, and C. Li Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart PNAS, February 1, 2005; 102(5): 1767 - 1772. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |